Exhibit 99

Press Release

Contact:		Claire M. Gulmi
		Executive Vice President and
		Chief Financial Officer
		(615) 665-1283

AMSURG ANNOUNCES FOURTH-QUARTER NET EARNINGS

FROM CONTINUING OPERATIONS OF $0.43 PER DILUTED SHARE

ESTABLISHES 2011 FINANCIAL GUIDANCE

NASHVILLE, Tenn. — (February 24, 2011) — Christopher A. Holden, President and Chief Executive Officer of AmSurg Corp. (NASDAQ: AMSG), today announced financial results for the fourth quarter and year ended December 31, 2010. Revenues increased 11% to $184,724,000 for the quarter from $166,002,000 for the fourth quarter of 2009. Net earnings from continuing operations attributable to AmSurg common shareholders for the fourth quarter of 2010 were $13,222,000, or $0.43 per diluted share, compared with $12,729,000, or $0.41 per diluted share, for the fourth quarter of 2009. The results for the fourth quarter of 2010 included an incremental negative impact of $0.01 per diluted share from the revision of the Medicare payment system for ASCs and $0.04 per diluted share from the higher interest costs related to the refinancing of the Company’s credit facility in May 2010, as previously disclosed.

     Revenues for the year ended December 31, 2010 increased 8% to $710,409,000 from $658,223,000 for 2009. Net earnings from continuing operations attributable to AmSurg common shareholders were $51,947,000, or $1.69 per diluted share, for 2010 compared with $51,826,000, or $1.68 per diluted share, for 2009. The results for 2010 included an incremental negative impact of $0.06 per diluted share from the revision of the Medicare payment system for ASCs and $0.10 per diluted share from the higher interest costs related to the refinancing of the Company’s credit facility.

     Mr. Holden remarked, “AmSurg’s comparable-quarter results strengthened for the fourth quarter of 2010, with an 11% increase in revenues and 5% growth in per-share earnings, after slight declines for the two previous quarters. Procedure growth of 9% contributed to our revenue growth for the quarter, as did a 2% increase in average revenue per procedure, which we attribute primarily to procedure mix. With same-center revenues flat with the fourth quarter of 2009, our procedure growth reflected the expansion in the average number of centers in operation for the fourth quarter of 2010 to 202 from 190 for the fourth quarter of 2009. Despite the deleveraging impact of flat same-center revenues, our continued focus on cost management and efficiency initiatives produced improved comparable-quarter EBITDA less noncontrolling interests as a percentage of revenues for the second consecutive quarter.

     “We acquired three additional centers during the fourth quarter and seven for the full year. We classified five centers as discontinued operations during the fourth quarter and expect final disposition of the centers to generate sales proceeds of approximately $5 million. We had expected to complete the acquisition of seven other centers under letter of intent by the end of

-MORE-

AMSG Reports Fourth-Quarter Results
Page 2
February 24, 2011

2010. We have now completed one of these acquisitions, executed purchase agreements contingent on regulatory approval for another two of the centers and expect to complete the acquisition of the remaining four centers near the end of the first quarter. These seven centers are included in the eight centers we had under letter of intent at the end of 2010. We also have one center under development, which we expect to open in 2011.

     “Net cash flows from operating activities for the fourth quarter of 2010 were $65.8 million, and distributions to noncontrolling interests, which are included in net cash flows from financing activities, were $33.4 million. Operating net cash flows less these distributions totaled $32.4 million for the fourth quarter, with which we funded capital expenditures for the quarter of $5.8 million and acquisitions of $12.1 million. We also reduced our debt during the fourth quarter and completed the quarter with a ratio of total debt to trailing 12 months EBITDA of 2.3 compared with 2.6 at the end of 2009. At the end of 2010, we had cash and cash equivalents of $34.1 million and availability under our revolving credit facility of $187.0 million.

     “Our guidance for 2011 includes the impact of headwinds from the last year of the four-year phase-in of the revised Medicare payment system, the partial year impact of the 2010 refinancing of our revolving credit facility and an increased effective tax rate. In addition, based on our same-center performance in the first quarter to-date and ongoing concern about high unemployment and sluggish economic conditions, we expect continuing negative leverage from flat to declining same-center procedures for 2011. As a result, we today established the following guidance for the 2011 fiscal year and for the first quarter of 2011:

	•		Revenues in a range of $740 million to $770 million for 2011.
	•		Same-center revenues in a range of 0% to a negative 1% for 2011.
	•		The addition of 18 to 20 new centers for the year.
	•		Net cash flow provided by operating activities, less distributions to noncontrolling interests, in a range of $90 million to $95 million.
	•		Net earnings from continuing operations per diluted share attributable to common shareholders for 2011 in a range of $1.64 to $1.68, which includes a negative $0.05 impact from the effect of the revised Medicare payment system and a negative $0.07 impact from higher interest costs related to the refinancing of our revolving credit facility and from the higher effective tax rate.
	•		Net earnings from continuing operations per diluted share attributable to common shareholders for the first quarter of 2011 in a range of $0.37 to $0.39 per diluted share, including a negative $0.01 impact from the effect of the revised Medicare payment system revision and a negative $0.04 impact from the higher interest costs related to the refinancing of our credit facility and from the higher effective tax rate.”

     The information contained in the preceding paragraphs is forward-looking information, and the attainment of these targets is dependent not only on AmSurg’s achievement of its assumptions discussed above, but also on the risks and uncertainties listed below that could cause actual results, performance or developments to differ materially from those expressed or implied by this forward-looking information.

     Mr. Holden concluded, “The strong headwinds AmSurg has faced during 2010 will affect our financial results for 2011. While we continue to focus on offsetting the deleveraging effect

-MORE-

AMSG Reports Fourth-Quarter Results
Page 3
February 24, 2011

of weak same-center revenue performance through initiatives to reengineer, automate and simplify our operations, our guidance anticipates significant margin pressure for 2011.

     “Our outlook for 2012 is substantially better. While we have limited visibility as to the timing or sustainability of any strengthening in the nation’s economic environment, we believe that our operating structure enables us to produce operating leverage with a relatively small sustained increase in same-center revenues. In addition, we expect our results for 2012 to benefit from:

	•		the completion of reductions in Medicare rate reimbursement in 2011, with no scheduled reduction in Medicare rates for 2012 for the first time in four years;
	•		the cycling at the end of May 2011 of the comparative negative impact of our refinancing at the end of May 2010;
	•		no expected negative comparative impact for changes in our effective tax rate.

     “With our leading GI and ophthalmology market share and the growing recognition of the high quality ASCs offer in the most affordable modality for many surgical procedures, we are confident that we are strongly positioned to benefit from clear demographic trends and from health care reform. In addition, we have a strong financial position and a robust pipeline of prospective center acquisitions. We are also continuously focused on ensuring that we are the strategic partner of choice for physicians. In pursuit of that goal, we achieved further material gains in physician satisfaction during 2010. As a result and despite the challenges we face in 2011, we are confident of our direction, our resources and our opportunities for long-term growth in earnings and shareholder value.”

     AmSurg Corp. will hold a conference call to discuss this release today at 5:00 p.m. Eastern time. Investors will have the opportunity to listen to the conference call over the Internet by going to www.amsurg.com and clicking “Investors” or by going to www.earnings.com at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available at these sites shortly after the call and continue for 30 days.

     This press release contains forward-looking statements. These statements, which have been included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, involve risks and uncertainties. Investors are hereby cautioned that these statements may be affected by the important factors, among others, set forth in AmSurg’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and other filings with the Securities and Exchange Commission, including the following risks: adverse impacts on the Company’s business associated with current and future economic conditions; the risk that payments from third-party payors, including government healthcare programs, may decrease or not increase as the Company’s costs increase; adverse developments affecting the medical practices of the Company’s physician partners; the Company’s ability to maintain favorable relations with its physician partners; the Company’s ability to acquire and develop additional surgery centers on favorable terms; the Company’s ability to grow revenues by increasing procedure volume while maintaining its operating margins and profitability at its existing centers; the Company’s ability to manage the growth in its business; the Company’s ability to

-MORE-

AMSG Reports Fourth-Quarter Results
Page 4
February 24, 2011

obtain sufficient capital resources to complete acquisitions and develop new surgery centers; the Company’s ability to compete for physician partners, managed care contracts, patients and strategic relationships; adverse weather and other factors that may affect the Company’s surgery centers; the Company’s failure to comply with applicable laws and regulations; the risk of changes in legislation, regulations or regulatory interpretations that may negatively affect the Company; the risk of becoming subject to federal and state investigation; the risk of regulatory changes that may obligate the Company to buy out interests of physicians who are minority owners of its surgery centers; potential liabilities associated with the Company’s status as a general partner of limited partnerships; liabilities for claims brought against our facilities; the Company’s legal responsibility to minority owners of its surgery centers, which may conflict with its interests and prevent it from acting solely in its best interests; risks associated with the potential write-off of the impaired portion of intangible assets; and potential liability relating to the tax deductibility of goodwill. Consequently, actual results, performance or developments may differ materially from the forward-looking statements included above. AmSurg disclaims any intent or obligation to update these forward-looking statements.

     AmSurg Corp. acquires, develops and operates ambulatory surgery centers in partnership with physician practice groups throughout the United States. At December 31, 2010, AmSurg owned a majority interest in 204 continuing centers in operation and had one center under development.

-MORE-

AMSG Reports Fourth-Quarter Results
Page 5
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

		For the Three Months								For the Twelve Months
		Ended December 31,								Ended December 31,
		2010				2009				2010				2009
Statement of Earnings Data:
Revenues		$	184,724			$	166,002			$	710,409			$	658,223
Operating expenses:
Salaries and benefits			56,576				49,898				213,274				197,569
Supply cost			24,293				21,131				94,064				81,607
Other operating expenses			37,058				34,826				148,878				134,574
Depreciation and amortization			6,427				5,697				24,910				22,351
Total operating expenses			124,354				111,552				481,126				436,101
Operating income			60,370				54,450				229,283				222,122
Interest expense			4,386				1,768				13,371				7,647
Earnings from continuing operations before income taxes			55,984				52,682				215,912				214,475
Income tax expense			8,653				8,669				34,324				35,067
Net earnings from continuing operations			47,331				44,013				181,588				179,408
Discontinued operations:
Earnings from operations of discontinued interest in surgery centers, net of income tax			525				697				1,640				2,644
Loss on disposal of discontinued interest in surgery centers, net of income tax			(2,635	)			(850	)			(2,732	)			(702	)
Net (loss) earnings from discontinued operations			(2,110	)			(153	)			(1,092	)			1,942
Net earnings			45,221				43,860				180,496				181,350
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations			34,109				31,284				129,641				127,582
Net earnings from discontinued operations			244				427				1,030				1,620
Total net earnings attributable to noncontrolling interests			34,353				31,711				130,671				129,202
Net earnings attributable to AmSurg Corp. common shareholders		$	10,868			$	12,149			$	49,825			$	52,148
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		$	13,222			$	12,729			$	51,947			$	51,826
Discontinued operations, net of income tax			(2,354	)			(580	)			(2,122	)			322
Net earnings attributable to AmSurg Corp. common shareholders		$	10,868			$	12,149			$	49,825			$	52,148
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.44			$	0.42			$	1.72			$	1.69
Net (loss) earnings from discontinued operations attributable to AmSurg Corp. common shareholders			(0.08	)			(0.02	)			(0.07	)			0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.36			$	0.40			$	1.65			$	1.71
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.43			$	0.41			$	1.69			$	1.68
Net (loss) earnings from discontinued operations attributable to AmSurg Corp. common shareholders			(0.08	)			(0.02	)			(0.07	)			0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.35			$	0.40			$	1.62			$	1.69
Weighted average number of shares and share equivalents (000’s):
Basic			30,318				30,206				30,255				30,576
Diluted			30,763				30,686				30,689				30,862

-MORE-

AMSG Reports Fourth-Quarter Results
Page 6
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands, except per share amounts)

		For the Three Months								For the Twelve Months
		Ended December 31,								Ended December 31,
		2010				2009				2010				2009
Operating Data:
Continuing centers in operation at end of period			204				197				204				197
New centers added during the period			3				8				7				14
Centers discontinued during the period			5				—				5				1
Centers under development/not opened at end of period			1				1				1				1
Centers under letter of intent			8				1				8				1
Average number of centers in operation			202				190				200				188
Average revenue per center		$	914			$	874			$	3,552			$	3,501
Same center revenues (decrease) increase			0	%			1	%			(2	%)			0	%
Procedures performed during the period			331,729				305,129				1,276,231				1,215,784
Income tax expense attributable to noncontrolling interests		$	31			$	200			$	628			$	639
Reconciliation of net earnings to EBITDA (1):
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	13,222			$	12,729			$	51,947			$	51,826
Add: income tax expense			8,653				8,669				34,324				35,067
Add: interest expense, net			4,386				1,768				13,371				7,647
Add: depreciation and amortization			6,427				5,697				24,910				22,351
EBITDA		$	32,688			$	28,863			$	124,552			$	116,891

-MORE-

AMSG Reports Fourth-Quarter Results
Page 7
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands)

		December 31,				December 31,
		2010				2009
Balance Sheet Data:
Assets
Current assets:
Cash and cash equivalents		$	34,147			$	29,377
Accounts receivable, net of allowance of $13,070 and $12,375, respectively			67,617				66,886
Supplies inventory			10,157				8,745
Deferred income taxes			1,509				2,324
Prepaid and other current assets			18,660				15,408
Current assets held for sale			866				34
Total current assets			132,956				122,774
Property and equipment, net			119,167				120,158
Goodwill			894,497				813,876
Intangible assets, net			11,361				9,797
Long-term assets held for sale			7,897				170
Long-term receivables			—				56
Total assets		$	1,165,878			$	1,066,831
Liabilities and Equity
Current liabilities:
Current portion of long-term debt		$	6,648			$	5,989
Accounts payable			15,291				14,821
Accrued salaries and benefits			17,952				18,156
Other accrued liabilities			3,136				3,208
Income taxes payable			—				402
Current liabilities held for sale			536				37
Total current liabilities			43,563				42,613
Long-term debt			283,215				296,783
Deferred income taxes			90,089				71,665
Other long-term liabilities			24,404				22,036
Noncontrolling interests — redeemable			147,740				123,363
Equity:
Common stock, no par value 70,000,000 shares authorized, 31,039,770 and 30,674,525 shares outstanding, respectively			171,522				163,729
Retained earnings			393,061				343,236
Accumulated other comprehensive loss, net of income taxes			(515	)			(1,849	)
Total AmSurg Corp. equity			564,068				505,116
Noncontrolling interests — non-redeemable			12,799				5,255
Total equity			576,867				510,371
Total liabilities and equity		$	1,165,878			$	1,066,831

-MORE-

AMSG Reports Fourth-Quarter Results
Page 8
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data, continued
(Dollars in thousands)

		For the Three Months								For the Twelve Months
		Ended December 31,								Ended December 31,
		2010				2009				2010				2009
Statement of Cash Flow Data:
Cash flows from operating activities:
Net earnings		$	45,221			$	43,860			$	180,496			$	181,350
Adjustments to reconcile net earnings to net cash flows provided by operating activities:
Depreciation and amortization			6,427				5,697				24,910				22,351
Net loss on sale and impairment of long-lived assets			4,084				21				4,243				455
Share-based compensation			1,444				966				4,869				4,068
Excess tax benefit from share-based compensation			(119	)			(5	)			(200	)			(32	)
Deferred income taxes			4,830				3,464				18,247				14,703
Increase (decrease) in cash and cash equivalents, net of effects of acquisition and dispositions, due to changes in:
Accounts receivable, net			3,666				3,596				713				1,494
Supplies inventory			(901	)			(418	)			(541	)			(60	)
Prepaid and other current assets			(3,184	)			(1,754	)			(3,364	)			(733	)
Accounts payable			2,033				2,233				(220	)			1,289
Accrued expenses and other liabilities			2,116				(1,473	)			168				6,666
Other, net			202				347				1,254				1,033
Net cash flows provided by operating activities			65,819				56,534				230,575				232,584
Cash flows from investing activities:
Acquisition of interest in surgery centers and related transactions			(12,075	)			(76,121	)			(53,690	)			(95,826	)
Acquisition of property and equipment			(5,775	)			(3,421	)			(19,275	)			(19,930	)
Proceeds from the sale of surgery centers			60				400				60				1,298
Repayment of notes receivable			—				—				—				1,666
Net cash flows used in investing activities			(17,790	)			(79,142	)			(72,905	)			(112,792	)
Cash flows from financing activities:
Proceeds from long-term borrowings			20,030				84,719				176,619				137,178
Repayment on long-term borrowings			(31,423	)			(29,902	)			(195,960	)			(116,951	)
Distributions to noncontrolling interests			(33,449	)			(33,660	)			(132,110	)			(130,855	)
Proceeds from issuance of common stock upon exercise of stock options			1,900				23				2,583				201
Repurchase of common stock			—				—				—				(12,587	)
Capital contributions and ownership transactions by noncontrolling interests			160				178				224				1,036
Excess tax benefit from share-based compensation			119				5				200				32
Financing cost incurred			(16	)			(6	)			(4,456	)			(17	)
Net cash flows (used in) provided by financing activities			(42,679	)			21,357				(152,900	)			(121,963	)
Net increase (decrease) in cash and cash equivalents			5,350				(1,251	)			4,770				(2,171	)
Cash and cash equivalents, beginning of period			28,797				30,628				29,377				31,548
Cash and cash equivalents, end of period		$	34,147			$	29,377			$	34,147			$	29,377

-MORE-

AMSG Reports Fourth-Quarter Results
Page 9
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

Presented below is certain statement of earnings and operating data for prior quarterly periods in 2010, which have been restated in order to include additional discontinued operations.

														For the Nine
		For the Three Months Ended												Months Ended
		March 31,				June 30,				Sept. 30,				Sept. 30,
		2010				2010				2010				2010
Statement of Earnings Data:
Revenues		$	170,116			$	177,498			$	178,071			$	525,685
Operating expenses:
Salaries and benefits			51,176				51,811				53,711				156,698
Supply cost			22,778				23,285				23,708				69,771
Other operating expenses			36,800				38,006				37,014				111,820
Depreciation and amortization			5,662				5,850				6,971				18,483
Total operating expenses			116,416				118,952				121,404				356,772
Operating income			53,700				58,546				56,667				168,913
Interest expense			1,839				3,135				4,011				8,985
Earnings from continuing operations before income taxes			51,861				55,411				52,656				159,928
Income tax expense			8,621				9,252				7,798				25,671
Net earnings from continuing operations			43,240				46,159				44,858				134,257
Net earnings from discontinued operations			272				469				277				1,018
Net earnings			43,512				46,628				45,135				135,275
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations			30,554				33,194				31,784				95,532
Net earnings from discontinued operations			261				292				233				786
Total net earnings attributable to noncontrolling interests			30,815				33,486				32,017				96,318
Net earnings attributable to AmSurg Corp. common shareholders		$	12,697			$	13,142			$	13,118			$	38,957
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		$	12,686			$	12,965			$	13,074			$	38,725
Discontinued operations, net of income tax			11				177				44				232
Net earnings attributable to AmSurg Corp. common shareholders		$	12,697			$	13,142			$	13,118			$	38,957
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.42			$	0.43			$	0.43			$	1.28
Net earnings from discontinued operations attributable to AmSurg Corp. common shareholders			0.00				0.01				0.00				0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.42			$	0.43			$	0.43			$	1.29
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.41			$	0.42			$	0.43			$	1.26
Net earnings from discontinued operations attributable to AmSurg Corp. common shareholders			0.00				0.01				0.00				0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.41			$	0.43			$	0.43			$	1.27
Weighted average number of shares and share equivalents (000’s):
Basic			30,212				30,239				30,251				30,234
Diluted			30,716				30,655				30,620				30,663

-MORE-

AMSG Reports Fourth-Quarter Results
Page 10
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

Presented below is certain statement of earnings and operating data for 2009, which have been restated in order to present additional discontinued operations.

																		For the Year
		For the Three Months																Ended
		March 31,				June 30,				Sept. 30,				Dec. 31,				Dec. 31,
		2009				2009				2009				2009				2009
Statement of Earnings Data:
Revenues		$	160,823			$	166,122			$	165,276			$	166,002			$	658,223
Operating expenses:
Salaries and benefits			48,331				48,702				50,638				49,898				197,569
Supply cost			19,655				20,685				20,136				21,131				81,607
Other operating expenses			33,145				33,679				32,924				34,826				134,574
Depreciation and amortization			5,495				5,553				5,606				5,697				22,351
Total operating expenses			106,626				108,619				109,304				111,552				436,101
Operating income			54,197				57,503				55,972				54,450				222,122
Interest expense			1,990				2,002				1,887				1,768				7,647
Earnings from continuing operations before income taxes			52,207				55,501				54,085				52,682				214,475
Income tax expense			8,416				9,192				8,790				8,669				35,067
Net earnings from continuing operations			43,791				46,309				45,295				44,013				179,408
Net earnings (loss) from discontinued operations			524				544				1,027				(153	)			1,942
Net earnings			44,315				46,853				46,322				43,860				181,350
Less net earnings attributable to noncontrolling interests:
Net earnings from continuing operations			31,378				32,778				32,142				31,284				127,582
Net earnings from discontinued operations			321				495				377				427				1,620
Total net earnings attributable to noncontrolling interests			31,699				33,273				32,519				31,711				129,202
Net earnings attributable to AmSurg Corp. common shareholders		$	12,616			$	13,580			$	13,803			$	12,149			$	52,148
Amounts attributable to AmSurg Corp. common shareholders:
Earnings from continuing operations, net of income tax		$	12,413			$	13,531			$	13,153			$	12,729			$	51,826
Discontinued operations, net of income tax			203				49				650				(580	)			322
Net earnings attributable to AmSurg Corp. common shareholders		$	12,616			$	13,580			$	13,803			$	12,149			$	52,148
Earnings per share-basic:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.40			$	0.44			$	0.44			$	0.42			$	1.69
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders			0.01				0.00				0.02				(0.02	)			0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.40			$	0.44			$	0.46			$	0.40			$	1.71
Earnings per share-diluted:
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	0.40			$	0.44			$	0.43			$	0.41			$	1.68
Net earnings (loss) from discontinued operations attributable to AmSurg Corp. common shareholders			0.01				0.00				0.02				(0.02	)			0.01
Net earnings attributable to AmSurg Corp. common shareholders		$	0.40			$	0.44			$	0.45			$	0.40			$	1.69
Weighted average number of shares and share equivalents (000’s):
Basic			31,244				30,660				30,195				30,206				30,576
Diluted			31,406				30,828				30,497				30,686				30,862

-MORE-

AMSG Reports Fourth-Quarter Results
Page 11
February 24, 2011

AMSURG CORP.
Unaudited Selected Consolidated Financial and Operating Data
(Dollars in thousands, except per share amounts)

Presented below is certain statement of earnings and operating data for 2010 and 2009, which have been restated in order to present additional discontinued operations.

														For the Nine
		For the Three Months Ended												Months Ended
		March 31,				June 30,				Sept. 30,				Sept. 30,
		2010				2010				2010				2010
Operating Data:
Procedures			303,259				319,229				322,014				944,502
Reconciliation of net earnings to EBITDA (1):
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	12,686			$	12,965			$	13,074			$	38,725
Add: income tax expense			8,621				9,252				7,798				25,671
Add: interest expense, net			1,839				3,135				4,011				8,985
Add: depreciation and amortization			5,662				5,850				6,971				18,483
EBITDA		$	28,808			$	31,202			$	31,854			$	91,864

																		For the Year
		For the Three Months																Ended
		March 31,				June 30,				Sept. 30,				Dec. 31,				Dec. 31,
		2009				2009				2009				2009				2009
Operating Data:
Procedures			297,633				308,039				304,983				305,129				1,215,784
Reconciliation of net earnings to EBITDA (1):
Net earnings from continuing operations attributable to AmSurg Corp. common shareholders		$	12,413			$	13,531			$	13,153			$	12,729			$	51,826
Add: income tax expense			8,416				9,192				8,790				8,669				35,067
Add: interest expense, net			1,990				2,002				1,887				1,768				7,647
Add: depreciation and amortization			5,495				5,553				5,606				5,697				22,351
EBITDA		$	28,314			$	30,278			$	29,436			$	28,863			$	116,891

-END-